Theme: Prospects and Development of Prophylactic & Therapeutic Vaccines

The 9th Global Summit and Expo on Vaccines & Vaccination to be held at San Francisco, USA. during Nov 30-Dec 02, 2015 hosted by OMICS Group Conferences through the theme "Prospects and Development of Prophylactic & Therapeutic Vaccines", conference will explore the advances in Vaccines and vaccination. This conference could be an exceptional event that brings along a novel and International mixture of giant and medium cognizance on vaccines and vaccination, leading universities engendering the conference an ideal platform to apportion expertise, foster collaborations across trade and world, and assess elevating technologies across the world. OMICS International Publishes 400+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members and Organizes 300+ Conferences every year across USA, Europe & Asia with support from 1000 more scientific societies.

Vaccination is a key to eradicate the diseases. It is a subject for the professionals who looks beyond the clinical prospects. Vaccines -2015 amasses all the extroverts under one roof of current advances.

Importance & Scope:

Vaccinology is a major field in eradication of diseases. Traditional approaches to vaccine design were to emasculate or inactivate the human pathogen or a cognate animal homologue, Vaccinology is the science of vaccine development and how the immune system responds to vaccines, but additionally includes perpetual evaluation of immunization programs and vaccine safety and efficacy, as well as surveillance of the epidemiology of vaccine-preventable diseases. This chapter provides a brief overview of some of the main concepts of immunology and vaccinology as they relate to immunization.

Why San Francisco?

San Francisco, More than 50,000 people die in the U.S each year from diseases that could have been prevented with a simple vaccine. Influenza is by far the biggest killer, but there are also regular outbreaks of measles, meningitis, and pertussis. Ebola virus and Pertussis (or whooping cough) is currently epidemic in California. Unvaccinated people can spread disease to other adults and the children too young to be immunized. These are the some of the Global market research analysis for Vaccines approved by BCC. Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in 2012 to $43.4 billion in 2017, for DNA vaccines was valued at $305.3 million in 2014, and further to $2.7 billion by 2019, influenza market will grow from nearly $6 billion in 2018. The protein therapeutics market is expected to decline to $136.7 billion in 2013 and then increase to nearly $179.1 billion in 2018, for Multiple Sclerosis (MS) disease-modifying products is expected to grow to nearly $14.2 billion in 2018. The global protein therapeutics market is expected to decline to $136.7 billion in 2013 and then increase to nearly $179.1 billion in 2018, a compound annual growth rate (CAGR) of 5.6% over the five-year period from 2013 to 2018.

Why to attend???

Vaccines -2015 could be an event that brings along a novel and International mixture of giant and medium Vaccinology innovation and incipient trends in vaccines and vaccination, leading universities and vaccinology, vaccination research analysis establishments creating the conference an ideal platform to share expertise, foster collaborations across trade and world, and assess rising technologies across the world. World-renowned speakers, the most recent techniques, tactics, and the newest updates in Vaccinology research are hallmarks of this conference.

A Unique Opportunity for Advertisers and Sponsors at this International event:

9 University of Texas Southwestern Medical Center--DallasUniversity of California San Franciso

Companies Associated with Vaccines

· CareDx

· Atara

· Biotherapeutics

· Benitec Limited

· InterMune

· Biotron Limited

· BioDiem

· Antisense Therapeutics Limited

· GlaxoSmithKline Australia Pty Ltd

· Bionomics

· Australian Pharmaceutical Industries (API)

· BioPharmica Limited

Market Analysis of Vaccines

The Global market research analysis for Vaccines approved by BCC. Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in 2012 to $43.4 billion in 2017, for DNA vaccines was valued at $305.3 million in 2014, and further to $2.7 billion by 2019, influenza market will grow from nearly $6 billion in 2018. The protein therapeutics market is expected to decline to $136.7 billion in 2013 and then increase to nearly $179.1 billion in 2018, for Multiple Sclerosis (MS) disease-modifying products is expected to grow to nearly $14.2 billion in 2018. The global protein therapeutics market is expected to decline to $136.7 billion in 2013 and then increase to nearly $179.1 billion in 2018, a compound annual growth rate (CAGR) of 5.6% over the five-year period from 2013 to 2018.